Top Investors - Biotech, Part 2

Part
01
of six
Part
01

Top Investors - Biotech: Alexandria Venture, Perceptive Advisors

Alexandria Investment was founded in 1996 and is headquartered in San Francisco. Partners Perceptive Advisors was founded in 1999 and is headquartered in New York.

Alexandria Venture Investments

  • Alexandria Venture Investments (AVI) is the venture capital arm of Alexandria Real Estate Equities, which is listed on the New York Stock Exchange with the ticker symbol ARE.
  • AVI was founded in 1996 to provide "long-term strategic investment capital " to companies developing "breakthrough technologies and therapies" in specific sectors.
  • The sectors it invests in are AgTech, technology, diagnostics, biopharma, and research tools.
  • It invests at different stages including, seed, early, and growth-stage.
  • In 2018, AVI was named the "Most Active Biopharma Investor" by new deal volume, by Sillicon Valley Bank.
  • In the same year, it was named the "#1 venture capital investor in the healthcare sector by U.S.-based deal volume", by Forbes.
  • The company is headquartered in San Francisco — California and employs 251+ people.

Investments

Points of Contact

Data from Initial Research


Perceptive Advisors

  • Perceptive Advisors is focused on "supporting progress in the life sciences industry", by spotting opportunities and administering financial resources towards "the most promising" technologies in modern healthcare.
  • The firm was established in 1999 and is headquartered in New York, New York.
  • It states that its investments are targeted towards healthcare companies from small to large, who have been identified in their fields as being transformative.
  • It also looks out for companies who offer new therapeutics, devices, or diagnostics with conviction in the healthcare industry.
  • The company is made up of 26 team members and has approximately $4.2 billion in assets under management.

Investments

  • In April 2020, Perceptive Advisors was the lead investor in a $55 million Series C investment into the company Dynacure. Dynacure is a biotech company specialized in the development of clinical-stage drugs for patients with orphan and rare diseases.
  • In March 2020, Perceptive Advisors through its Perceptive Xontogeny Venture Fund, invested $21 million in a Series A financing into Zucara Therapeutics. Zucara Therapeutics is a biotech company focused on creating the "first, once-daily" therapeutic, for preventing low blood sugar in diabetic patients.

Points of Contact

Data From Initial Research


Part
02
of six
Part
02

Top Investors - Biotech: ARCH Venture Partners, Google Ventures

Arch Venture Partners was founded in 1986 and is headquartered in Chicago. Google Ventures was founded in 2009 and is headquartered in Mount View, California.

Arch Venture Partners

Overview

Investments

  • Some portfolio companies that are working to fight the COVID-19 pandemic include Vir Biotechnology, VBI Vaccines, Brii Biosciences, Alnylam Pharmaceuticals, Sana Biotechnology, Quanterix, Twist Biosciences, and Bellerophon. It is noted that none of the investments were made in these companies over the past five months.

Points of Contact

Initial Research


Google Ventures (GV)

Overview

  • Google Ventures was spun out of Google in 2009, and it is the venture capital subsidiary of Alphabet, Inc. The company is headquartered in Mountain View, California, and has offices located in Boston, San Francisco, New York, and London.
  • The venture capital funding company invests in bold new companies across the domains of life science, consumer products and services, enterprise technology, and frontier technology.
  • GV manages an active portfolio of 300 companies, valued at $4.5 billion. The company facilitates startups with unique technology powered by Google.

Investments

Points of Contact

Initial Research

Part
03
of six
Part
03

Top Investors - Biotech: Boxer Capital, OrbiMed

Boxer Capital is based in San Diego, California, and invests in drug development. OrbiMed is a private investment firm based in New York and was established in 1989.

Boxer Capital

  • Boxer Capital is based in San Diego, California. The firm invests in "drug development across multiple therapeutic indications".
  • Boxer Capital was established in 2005 by Tavistock Group.
  • The firm invests in companies that have goals of improving medicine. Boxer Capital's research and investment team identifies investment opportunities "throughout the business life-cycle".

Investments

  • Boxer Capital has invested in a total of seven biotechnology companies in the past five months. Examples include Pandion Therapeutics and Tango Therapeutics.
  • In early April 2020, Boxer Capital led a $60 million Series B financing round for Tango Therapeutics. Tango Therapeutics is "a biotech company focused on discovering and delivering the next generation of targeted cancer therapies".
  • Boxer Capital also participated in an $80 million Series B financing round for Pandion Therapeutics, Inc in early April 2020. Pandion Therapeutics is a biotech company with the aim of finding the treatment of autoimmune disorders.

Additional Points of Contact

OrbiMed

  • OrbiMed is a private investment firm based in New York. The company invests in biopharmaceuticals, medical devices, healthcare services, and diagnostics innovations globally.
  • The investment business was established in 1989.

Investments

  • OrbiMed has invested in a total of ten biotechnology companies in the past five months. Examples include Pandion Therapeutics and Aspen Neuroscience.
  • In March 2020, OrbiMed participated in an $80 million Series A financing round for ReCode. ReCode is a private biotech company "pioneering precision medicines for pulmonary diseases".
  • April 01, 2020, OrbiMed led a $70 million Series A financing round for Aspen Neuroscience. Aspen Neuroscience is a "private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson's disease".

Additional Points of Contact

  • Stephen Squinto is an executive partner at OrbiMed. Here is the link to his LinkedIn account.
  • Carl L. Gordon is a founding "partner and co-head of Global Private Equity" at OrbiMed. Here is the link to his LinkedIn account.
  • Carter Neild is a general partner at OrbiMed. Here is the link to his LinkedIn account.
Part
04
of six
Part
04

Top Investors - Biotech: Redmile Group, Osage University Partners

Redmile Group invests in healthcare companies, while Osage University Partners (OUP) strictly invests in startups that are developing pioneering technologies. Redmile has assets worth $4.18 billion, while OUP has about $600 million under management.

Redmile Group

  • Founded in 2007, Redmile is a US-based "healthcare and life sciences investment firm" that has assets worth $4.18 billion.
  • It has locations in San Francisco, California and New York City, New York.
  • Redmile focuses on "venture, growth and crossover investing across healthcare."

Biotech Investments

  • In February 2020, Redmile collaborated with Sofinnova Partners to invest £26.3 million in Redx Pharma, which is a "UK-based oncology and fibrotic disease focused biotech company." Additionally, Redmile is providing "£5 million of short-term debt funding" to Redx. After the investment, Jeremy Green, the founder and portfolio manager of Redmile, said, "Redx, with its deep expertise in medicinal chemistry, has a proven track record of designing high quality, commercially attractive molecules that have the potential to be effective drugs to treat significant unmet medical conditions."
  • Redmile's most recent biotech investment was in LifeSprout, a "regenerative medicine company founded with technology licensed from Johns Hopkins University." Redmile's investment helped LifeSprout close "a $28.5 million Series A financing," which the firm will use toward developing products from its Regenerative Matrix platform. The Regenerative Matrix platform consists of "biomimetic, biocompatible materials engineered to look and feel like natural tissue."

Points of Contact at Biotech

Strategy Data: Biotech's investments in 2019 and 2020:

Osage University Partners

Osage University Partners' Investments

  • In March 2020, OUP invested in ReCode Therapeutics, "a biotech startup focused on precision medicine for pulmonary diseases." OUP's investment helped ReCode close "an $80 million Series A round."
  • In October 2019, OUP made an investment in IonQ, a Maryland-based quantum computing company. The investment helped the firm raise $55 million in funding, which IonQ wants to put toward commercializing its own quantum computing platform.

Points of Contact at Osage University Partners

Strategy Data: Osage University Partners' investments in 2019 and 2020:

Research Strategy

After searching Osage University Partners' website and social media platforms, as well as news publications, we found that OUP made only one biotech investment in the past five months. However, we expanded our research and discovered that OUP's last biotech investment in 2019 was in IonQ. Therefore, we've included this information above.
Part
05
of six
Part
05

Top Investors - Biotech: RA Capital, Johnson & Johnson Innovation

In the past five months RA Capital Management has invested in the biotechnology companies Pandion Therapeutics and the Legend Biotech Corporation, while Johnson & Johnson Innovation has also invested in the Legend Biotech Corporation. Additionally, Johnson & Johnson Innovation has invested in Adicet Bio.

RA Capital

  • Located in Boston, Massachusetts, RA Capital Management operates as a multi-stage investment manager that employs between 51 and 200 individuals, according to its LinkedIn profile. The types of companies that RA Capital Management typically invests in include life science and healthcare entities that actively create diagnostics, drugs, and medical devices. Founded in the year 2004, its investment team principals are Matthew Hammond, Jake Simson, Parker Cassidy, Derek DiRocco and Zach Scheiner.
  • Additional points of contact at RA Capital Management include the team's managing director Josh Resnick and venture associates Nathanial Brooks Horwitz and Chieze Ibeneche-Nnewihe.
  • It has invested in 22 different biotech companies, including 12 during 2019 and 2020. In the past five months, RA Capital has invested in a total of nine biotechnology companies, such as Pandion Therapeutics and Legend Biotech.
  • In early April 2020, RA Capital Management participated in an $80 million Series B financing round for Pandion Therapeutics, Inc., which acts as a clinical-stage biotechnology businesses that develops modular protein therapeutics meant for inflammatory and autoimmune illnesses. The company is currently headquartered in Cambridge, Massachusetts. Its chief executive officer is Rahul Kakkar, and Jo Viney serves as its co-founder, president, and chief scientific officer.
  • Also in early April 2020, RA Capital Management partook in a $150.5 million Series A financing round for the Legend Biotech Corporation. Legend Biotech is a clinical-stage biopharmaceutical business that focuses on the uncovering and progression of innovative cell therapies for indications such as oncology. The company plans to use the funds raised from this financing round to accelerate the development, commercialization, and research of its pipeline programs, as well as to expand it manufacturing establishments and improve "its research and development platform."
  • Founded in 2014 and headquartered in Piscataway, New Jersey, Yuan Xu is Legend Biotech's chief executive officer, and Frank Fan serves as its chief scientific officer and co-founder.

Johnson & Johnson

  • Johnson & Johnson Innovation consists of a network of complementary groups that offer significant tactics and solutions to promote collaborations. JJDC acts as Johnson & Johnson's strategic venture capital division. The group focuses its investments on providers of consumer healthcare, pharmaceuticals, and medical devices. Situated in Cambridge, Massachusetts, its venture investments principal is Vijay Murthy.
  • Additional points of contact include Tamir Meiri (senior manager of Venture Investments), Nicholas Mourlas (senior director of New Ventures), and Kara Bortone (senior director of sourcing and portfolio management).
  • The group has invested in a total of 25 biotech companies, including 11 during 2019 and 2020.
  • In the past five months, Johnson & Johnson Innovation has only made one investment in a biotechnology company, Legend Biotech. In early April, Johnson & Johnson Innovation participated in a $150.5 million Series A financing round for the Legend Biotech Corporation.
  • However, it has invested in about six biotechnology companies in the past 12 months (including Legend Biotech), such as Adicet Bio. In early October 2019, Johnson & Johnson Innovation took part in an $80 million Series B financing round for Adicet Bio, Inc. Adicet Bio is a pre-clinical stage biotechnology business that develops allogeneic cell therapies designed for cancer by utilizing gamma delta T cells.
  • Situated in Menlo Park, California, Anil Singhal is Adicet Bio's chief executive officer and president, and Stewart Abbot is its chief operating officer and chief scientific officer.
  • Additionally, it participated in a $100 million equity financing round for RefleXion Medical, a company in which it had already had previous investments in, in mid-April 2020. Headquartered in Hayward, California, RefleXion Medical operates as a therapeutic oncology organization that utilizes biology-guided radiotherapy to help cancer patients. The company's chief executive officer is Todd Powell.
Part
06
of six
Part
06

Top Investors - Biotech: IdieBio, US Department of Health

IndieBio invests $250,000 in fifteen early stage biology companies every six months. The HHS is the official government body that awards funding to select biology companies. Their funding for 2020 amounted to over $87 billion.

IndieBio

  • IndioBio is investing $250,000 in startups that are focused on developing “diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases.”
  • Every six months, fifteen early stage biology companies are selected for training in downtown San Francisco.
  • They have invested over $2.4 billion in 116 biology companies to date.
  • The company also opened a new office in Manhattan, New York recently.
  • While we were not able to find any specific investments that IndieBio has mad in the last month in biotech companies specifically, we did find that SOSV, their parent company, invested in Nordetect, a Copenhagen-based biotech company that produces "biosensors, hardware and data management systems for precision agriculture."
  • We did, however, find that IndieBio is in the process of selecting 8 biotech companies that are working on coronavirus-tech.
  • Contact information: Sam Lee (Program Director), Julie Wolf (Communications Director), Arvind Gupta (Managing Director), and Alex Kopeylan (Program Director and Partner).

US Department of Health (HHS)

  • The US Department of Health provides grants to multiple biology companies to "enhance and protect the health and well-being of all Americans."
  • Their budget for 2020 is "$87.1 billion in discretionary budget authority and $1.2 trillion in mandatory funding."
  • On March 31, Cure Health was awarded $13 million in funding by the HHS to develop a portable molecular test for the detection of the presence of the SARS-CoV-2 virus.
  • On March 30, 2020, the HHS announced a collaboration with Johnson & Johnson for the development of clinical tests and COVID-19 vaccines. Johnson & Johnson will invest $1 billion with the join collaboration of the HHS to develop over 1 billion vaccines for the virus.
  • The HHS also announced that it will support Moderna to speed up the Phase 2 and 3 clinical trials of its COVID-19 vaccine, SARS-CoV-2 mRNA-1273.
  • Alex M Azar is the Secretary of the HHS. His phone number is 202-690-7000 and his email is secretary@HHS.gov . He does not have a LinkeIn account but his Twitter account can be found here.
  • Other Contact information: Donald Rucker (National Coordinator for Health Information Technology), Michael Caputo (Assistant Secretary of HHS).

Research Strategy

While information for the HHS was readily available, information on the investments made by IndieBio in the last 5 months was not. We looked through the company's portfolio, press releases and industry publication like the IEEE, PR Newswire, and TechCrunch but we could not find any evidence that IndieBio has invested in any biotech companies since the beginning of January. The did invest in two agritech start-ups but the majority of the investments were made by their parent company, SOSV. It is also possible that they were saving their capital for the 8 biotech companies, which they are in the process of selecting.
Sources
Sources

From Part 01
From Part 02
From Part 05